Newswise — Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.
Researchers at the Korea Research Institute of Chemical Technology (KRICT), led by Dr. Chi Hoon Park, have successfully generated CAR-M (Chimeric Antigen Receptor Macrophages) by stably inserting synthetic genes into human macrophages derived from peripheral blood using a lentiviral delivery system. This breakthrough is expected to extend CAR therapy’s application beyond blood cancers to solid tumors.
CAR-T cell therapy involves extracting a patient’s T cells, genetically modifying them to target specific cancer cells, and reintroducing them into the patient. While…